SALT LAKE CITY, UT--(Marketwired - Jul 28, 2015) -  Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced today that it has created the design and methodology by which Nitric Oxide (NO) may well be safely delivered, at optimal levels, to facilitate in the therapeutic healing of chronic diabetic foot ulcers and wounds.

NO is a naturally-occurring molecule and a medically essential gas, widely recognized for its importance in a number of biological processes. NO has the potential for treating diseases ranging from malaria to tuberculosis to neonatal hypertension. Nu Med's focus is on developing medical applications for Nitric Oxide (NO). Among its many potential therapeutic uses, NO has been demonstrated to play an integral role in the wound healing process. Jeff Robins, President and CEO of Nu-Med Plus, Inc. remarked, "We are excited to have completed the design and methodology of our NO technology intended for use in diabetic foot wound healing. This advancement could potentially evolve into an appropriate therapy for diabetic foot wounds and ulcers, as well as possibly contribute to the increasing wound healing arena overall."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of Nitric Oxide gas for therapeutic use. For more information visit

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Contact Information:

Jeff Robins